These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

708 related items for PubMed ID: 9498162

  • 1. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
    Lissoni P, Fumagalli L, Paolorossi F, Rovelli F, Roselli MG, Maestroni GJ.
    J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162
    [Abstract] [Full Text] [Related]

  • 2. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P, Bolis S, Brivio F, Fumagalli L.
    Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
    [Abstract] [Full Text] [Related]

  • 3. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study.
    Lissoni P, Malugani F, Brivio F, Piazza A, Vintimilla C, Giani L, Tancini G.
    Neuro Endocrinol Lett; 2003; 24(3-4):259-62. PubMed ID: 14523367
    [Abstract] [Full Text] [Related]

  • 4. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
    Lissoni P, Malugani F, Malysheva O, Kozlov V, Laudon M, Conti A, Maestroni G.
    Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
    [Abstract] [Full Text] [Related]

  • 5. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
    Lissoni P, Brivio F, Fumagalli L, Messina G, Vigoré L, Parolini D, Colciago M, Rovelli F.
    Anticancer Res; 2008 Aug; 28(2B):1377-81. PubMed ID: 18505083
    [Abstract] [Full Text] [Related]

  • 6. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone.
    Lissoni P, Rovelli F, Frassineti A, Fumagalli L, Malysheva O, Conti A, Maestroni G.
    Neuro Endocrinol Lett; 2000 Aug; 21(4):319-323. PubMed ID: 11455367
    [Abstract] [Full Text] [Related]

  • 7. Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol.
    Lissoni P, Pittalis S, Rovelli F, Zecchini S, Casati M, Tremolada M, Pelizzoni F.
    J Biol Regul Homeost Agents; 1996 Aug; 10(1):27-30. PubMed ID: 9049779
    [Abstract] [Full Text] [Related]

  • 8. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent.
    Lissoni P.
    Pathol Biol (Paris); 2007 Aug; 55(3-4):198-200. PubMed ID: 17451889
    [Abstract] [Full Text] [Related]

  • 9. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, Fumagalli L, Bordoni A, Mengo S, Gardani GS, Tancini G.
    In Vivo; 2002 Aug; 16(2):93-6. PubMed ID: 12073777
    [Abstract] [Full Text] [Related]

  • 10. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms.
    Lissoni P.
    Ann N Y Acad Sci; 2000 Aug; 917():560-7. PubMed ID: 11268384
    [Abstract] [Full Text] [Related]

  • 11. Is there a role for melatonin in supportive care?
    Lissoni P.
    Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501
    [Abstract] [Full Text] [Related]

  • 12. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
    Lissoni P, Barni S, Ardizzoia A, Brivio F, Tancini G, Conti A, Maestroni GJ.
    J Biol Regul Homeost Agents; 1992 Mar; 6(4):132-6. PubMed ID: 1296454
    [Abstract] [Full Text] [Related]

  • 13. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
    Lissoni P, Brivio F, Brivio O, Fumagalli L, Gramazio F, Rossi M, Emanuelli G, Alderi G, Lavorato F.
    J Biol Regul Homeost Agents; 1995 Mar; 9(1):31-3. PubMed ID: 8553906
    [Abstract] [Full Text] [Related]

  • 14. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
    Lissoni P, Barni S, Ardizzoia A, Olivini G, Brivio F, Tisi E, Tancini G, Characiejus D, Kothari L.
    J Biol Regul Homeost Agents; 1993 Mar; 7(4):121-5. PubMed ID: 8023699
    [Abstract] [Full Text] [Related]

  • 15. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients.
    Lissoni P, Rovelli F, Brivio F, Fumagalli L, Brera G.
    In Vivo; 2008 Mar; 22(3):397-400. PubMed ID: 18610754
    [Abstract] [Full Text] [Related]

  • 16. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
    Lissoni P, Barni S, Brivio F, Rossini F, Fumagalli L, Tancini G.
    J Biol Regul Homeost Agents; 1995 Mar; 9(2):52-4. PubMed ID: 9127633
    [Abstract] [Full Text] [Related]

  • 17. Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study.
    Lissoni P, Vigorè L, Rescaldani R, Rovelli F, Brivio F, Giani L, Barni S, Tancini G, Ardizzoia A, Viganò MG.
    J Biol Regul Homeost Agents; 1995 Mar; 9(4):155-8. PubMed ID: 8844341
    [Abstract] [Full Text] [Related]

  • 18. Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer.
    Lissoni P, Pittalis S, Rovelli F, Vigorè L, Roselli MG, Brivio F.
    J Biol Regul Homeost Agents; 1995 Mar; 9(2):63-6. PubMed ID: 9127635
    [Abstract] [Full Text] [Related]

  • 19. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.
    Lissoni P.
    Pathol Biol (Paris); 2007 Mar; 55(3-4):201-4. PubMed ID: 17446010
    [Abstract] [Full Text] [Related]

  • 20. Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin.
    Brackowski R, Zubelewicz B, Romanowski W, Lissoni P, Barni S, Tancini G, Maestroni GJ.
    J Biol Regul Homeost Agents; 1994 Mar; 8(3):77-80. PubMed ID: 7754792
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.